Lung cancer trials in China

In China 1146 Also abroad 2733

1,146 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
Where
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
Age
18 years and over
People
554 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00
Phase 3Taking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Kunming, Lanzhou, Linhai, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
Age
18 years and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Jingzhou, Kunming, Linhai, Nanchang, Ningbo, Shanghai, Wenzhou, Wuhan, Xi'an, Xiangyang, Zhengzhou
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
Phase 1/2Taking people
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Where
Beijing, Hangzhou, Nanjing, Wuhan
Age
18 years and over
People
450 worldwide
Run by
Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00
Phase 1/2Taking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang, Shenzhen, Wuhan
Age
18 years and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
Phase 1/2Taking people
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
Where
Shanghai, Zhengzhou
Age
18 years and over
People
108
Run by
Avistone Pharmaceutical（Ningbo）Co., LTD.
See details and how to joinNCT07063329
Phase 2Taking people
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Where
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Taiyuan, Wenzhou, Xuzhou
Age
18 years and over
People
60
Run by
AstraZeneca
See details and how to joinNCT07295821
Phase 3Taking people
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
Where
Shanghai, Zhengzhou
Age
18 years and over
People
562
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07502300
Phase 2/3Not yet taking people in China
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
Where
Guangzhou
Age
18 years and over
People
166
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07739186
Phase 2Taking people
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
Age
18 years and over
People
128 worldwide
Run by
Teligene US
See details and how to joinNCT05168566
Phase 1/2Taking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Beijing, Changsha, Chengdu, Fuzhou, Kunming, Liuzhou, Nanchang, Nanjing, Shanghai, Taiyuan, Wuhan, Xi'an, Zhengzhou
Age
18 years and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou Fujian, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Nanyang, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2Taking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
Beijing, Chengdu, Nanchang, Shanghai, Wuhan, Zhengzhou
Age
18 years and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
Phase 2Taking people
Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma
Where
Beijing
Age
18 years and over
People
60
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07622706
Phase 1/2Not yet taking people in China
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Nanning, Shanghai
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00
No phaseNot yet taking people in China
Union-LC-MPE Cohort:A Multicenter Cohort Study on Diagnosis and Prognosis of Malignant Pleural Effusion in Lung Cance
Where
Wuhan
Age
18 years and over
People
3,000
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07882758
Phase 3Not yet taking people in China
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
Where
Shanghai
Age
18 years and over
People
425
Run by
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
See details and how to joinNCT07897188
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Chengdu, Guangzhou
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Early phase 1Taking people
mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors
Where
Beijing
Age
Up to 99 years
People
83
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06928922
Phase 2Taking people
D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
46
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT07016126
Early phase 1Taking people
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
Where
Nanjing
Age
18 years to 75 years
People
24
Run by
TCRCure Biopharma Ltd.
See details and how to joinNCT07246304
No phaseTaking people
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
Where
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou, Handan, Hefei, Huzhou, Jinan, Jining, Linhai, Linyi, Lishui, Liuzhou, Nanchang, Nanjing, Nanning, Nantong, Qiqihar, Shanghai, Shaoxing, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Suining, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Wuhan, Wuhu, Xiamen, Xi'an, Xiangyang, Yangzhou, Zhoushan, Zunyi
Age
18 years and over
People
1,000
Run by
AstraZeneca
See details and how to joinNCT07613424
No phaseTaking people
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Where
Shanghai
Age
18 years to 90 years
People
294
Run by
Shanghai Chest Hospital
See details and how to joinNCT07681245
No phaseTaking people
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Where
Beijing
Age
18 years to 85 years
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07894458
No phaseTaking people
Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
Where
Wuhan
Age
35 years and over
People
6,000
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07895277